UroGen Pharma Ltd. (URGN)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, UroGen Pharma Ltd. reported revenue of $72.5M, net income of -$14.4M, and total assets of $252.6M. Every figure below is taken directly from UroGen Pharma Ltd.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2016–FY2025 · as reported
- FY2016 revenue
- $17.5M
- FY2025 revenue
- $109.8M
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $109.8M | -$153.5M |
| FY2024 | $90.4M | -$126.9M |
| FY2023 | $82.7M | -$102.2M |
| FY2022 | $64.4M | -$109.8M |
| FY2021 | $48.0M | -$110.8M |
| FY2020 | $11.8M | -$128.5M |
| FY2019 | $18,000 | -$105.1M |
| FY2018 | $1.1M | -$75.7M |
| FY2017 | $8.2M | -$20.0M |
| FY2016 | $17.5M | -$1.9M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Aug 20, 2026 | on EDGAR ↗ |
| 8-K | Aug 5, 2026 | on EDGAR ↗ |
| 10-Q | Aug 5, 2026 | on EDGAR ↗ |
| 8-K | Jun 23, 2026 | on EDGAR ↗ |
| 8-K | Jun 2, 2026 | on EDGAR ↗ |
| 8-K | May 6, 2026 | on EDGAR ↗ |
| 10-Q | May 6, 2026 | on EDGAR ↗ |
| DEF 14A | Apr 30, 2026 | on EDGAR ↗ |
| 8-K | Mar 2, 2026 | on EDGAR ↗ |
| 10-K | Mar 2, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | — | — | source ↗ |
| EPS (basic) | $-0.28 | Earnings | source ↗ |
| Shares Outstanding | 48.9M | Entity | source ↗ |
| Cash from Operations | -$33.0M | Net | source ↗ |
| Cash from Financing | $500,000 | Net | source ↗ |
| Cash from Investing | $1.7M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
- Buys
- 0
- Sells
- 8
- Net shares
- -100.5K
Restatement history
Point-in-timeNo material restatements detected across 240 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
Deeper fundamentals
A free API key reaches URGN’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/URGN
MCP tool:
get_sec_fundamentals ticker=URGN - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/URGN/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=URGN as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/URGN/history
MCP tool:
get_fundamentals_history ticker=URGN - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/URGN
MCP tool:
get_financial_health ticker=URGN
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.